Autolus Therapeutics plc
AUTL· Nasdaq
AUTLAutolus Therapeutics plc
Source filing unavailable
| Metric | Q2 2019 | Q2 2018 |
|---|---|---|
| Revenue | $338.00K | $443.00K |
| Net Income | -$28.48M | -$7.65M |
| EPS Diluted | -$0.65 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
